MAPT and early-onset autosomal dominant Alzheimer disease: These findings suggest that while CSF 14-3-3β may not be as accurate as CSF p-tau and CSF t-tau in distinguishing CN Aβ− from Alzheimer’s disease Aβ+ or MCI Aβ+ groups, it may still be a promising biomarker for Alzheimer’s disease diagnosis, particularly when compared to plasma biomarkers such as plasma p-tau and plasma NfL.